The properties of Gd2O3-assembled silica nanocomposite targeted nanoprobes and their application in MRI.
The feasibility of the gadolinium-doped mesoporous silica nanocomposite Gd(2)O(3)@MCM-41 as a safe, effective MRI nanoprobe has been validated in the current investigation systematically from atomistic and molecular modeling to its synthesis and characterization on in vivo MR imaging and biocompatibility. The first-principles calculation indicates that it is nearly impossible for toxic Gd ions to dissociate freely from silica. The biocompatibility studies confirm that the nanocomposite is lack of any potential toxicity; the biodistribution studies reveal a greater accumulation of the nanocomposite in liver, spleen, lung and tumor than in kidney, heart and brain; the excretion studies show that the nanocomposite can be cleared nearly 50% via the hepatobiliary transport mechanism after 1.5 months of injection. A larger water proton relaxivity r(1) and a better T(1)-weighted phantom MR imaging capability were detected in the nanocomposite than in the commercially available gadolinium diethylenetriaminepentaacetate. The results demonstrate that the nanocomposite is superior to the commercial counterpart in terms of contrast enhancement with a satisfactory biocompatibility, and it has a high potential to be developed into a safe and effective targeted probe for in vivo molecular imaging of cancer.